












































































































Pitfalls in the Detection of Insulinomas With
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Purpose: Physiological pancreaticoduodenal uptake of radiolabeled exendin-4
in Brunner glands of the proximal duodenum is the most common pitfall for
false interpretation of glucagon-like peptide-1 receptor (GLP-1R) imaging.
The aim of this study was to analyze the pancreaticoduodenal uptake in
GLP-1R PET/CT and SPECT/CT images and to identify additional poten-
tial reading pitfalls in patients with suspected insulinoma.
Methods: A post hoc analysis of a prospective study, including 52 consec-
utive patients, was performed. All patients underwent 1 68Ga-exendin-4
PET/CT and 2 111In-exendin-4 SPECT/CT scans (4 and 72 hours postinjec-
tion) in a randomized crossover order. Three board-certified nuclear medi-
cine physicians read all scans independently. They were unaware of other
results. Reference standard was surgery with histopathological confirmation
of an insulinoma/nesidioblastosis and normalization of blood glucose levels
after surgery.
Results: There were no false-positive readings. However, there were a num-
ber of false-negative PET/CTand SPECT/CT readings, respectively: (1) due
to false interpretation of uptake in the pancreaticoduodenal region (falsely
interpreted as physiological uptake in Brunner glands instead of an insulinoma
in 0.6% vs 9.0%), (2) due to ectopic insulinoma (0% vs 2.6%), (3) due to
small insulinoma (1.9% vs 5.1%), (4) due to insulinoma overlap with kidneys
(1.9% vs 4.5%), and (5) due to nesidioblastosis (0.6% and 1.9%). Pitfalls were
identified in all GLP-1R PET/CT and SPECT/CT scans.
Conclusions: Peripancreatic uptake, small size of an insulinoma, insulinoma
overlap with kidneys, and presence of nesidioblastosis are potential pitfalls in
GLP-1R imaging, which can lead to false reading results.
Key Words: 68Ga-exendin-4, 111In-exendin-4, Brunner glands,
GLP-1R imaging, insulinoma, PET/CT, SPECT/CT
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G lucagon-like peptide-1 receptor (GLP-1R) imaging with PETor SPECT has become an essential diagnostic tool in the
detection of benign insulinomas in patients with endogenous
hyperinsulinemic hypoglycemia (EHH).1,2 Other indications include
(i) disease assessment in malignant insulinoma,3,4 (ii) detection of
clinically relevant lesions in patients with multiple endocrine neopla-
sia type 1 (MEN-1) and EHH,5 and (iii) detection of nesidioblastosis
in adults.1,6
In the first-ever prospectively executed GLP-1R study, 111In-
DTPA-exendin-4 SPECT/CT performed significantly better than
conventional imaging, that is, CT and/or MRI.1 Despite the high
sensitivity of GLP-1R SPECT/CT, some erroneous readings results
were encountered, partially misguiding the ensuing clinical proce-
dures. For example, in 1 patient, 111In-DTPA-exendin-4 SPECT/
CT revealed a focal uptake in the pancreatic head adjacent to the du-
odenum, as well as in the mesentery of the small bowel both sugges-
tive of an insulinoma.7 Because previously performed arterial
calcium stimulation with venous sampling (ASVS) likewise displayed
a pathological gradient in the area of the superior mesenteric artery, the
patient subsequently received a duodenopancreatectomy. However, no
insulinoma was visualized in the pancreatic head but in the mesentery
of the small bowel consistent with the second ectopic focal 111In-
DTPA-exendin-4 uptake. Immunohistochemistry of the resected
duodenum showed positive GLP-1R staining of the Brunner glands
(personal communication). This is in conjunction with previously
published data that Brunner glands can overexpress the GLP-1R.8
This might be the most reasonable explanation for the false-
positive pancreaticoduodenal finding in this patient.
In view of the described pitfall, as well as the possible
resulting clinical consequences, the aims of this study were to per-
form a post hoc analysis of our prospective acquired data to analyze
pancreaticoduodenal uptake in 111In-DOTA-exendin-4 SPECT/CT
and 68Ga-DOTA-exendin-4 PET/CT images and to identify addi-
tional pitfalls potentially leading to erroneous reading results.
MATERIALS AND METHODS
Study Design and Patients
A post hoc analysis of a prospective study, including 52 consec-
utive patients, was performed in order to identify and quantify pitfalls.
Patients were included if they had biochemically proven EHH with
neuroglycopenic symptoms and were excluded if the following condi-
tions were present: (i) evidence of a malignant insulinoma on conven-
tional imaging, (ii) pregnancy or breastfeeding in women, and (iii)
renal insufficiency (serum creatinine >140 μmol/L).
The regional scientific ethics committee approved the study,
and all patients provided written consent in accordance with provi-
sions of the Declaration of Helsinki.
Procedures
All patients underwent 1 PET/CTwith 43 to 106 MBq 68Ga-
DOTA-exendin-4 and 2 SPECT/CT scans with 52 to 111 MBq
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111In-DOTA-exendin-4, 4 and 72 hours postinjection, in a random-
ized crossover order within 3 to 4 days (Fig. 1). The reference standard
was successful surgery with histopathological/immunohistochemical
confirmation of an insulinoma. In 2 patients who refused surgery, 2 re-
petitiveMRI scans with follow-up of neuroglycopenic symptomswere
used as reference standard.
Detailed information about synthesis and labeling of 68Ga-
DOTA-exendin-4 and 111In- DOTA-exendin-4, co-administration
of glucose infusion, as well as scanning information, has been
published elsewhere.2
Reading and Image Analysis
All SPECT/CT and PET/CT images were analyzed using a
vendor-provided analysis software package (Syngo.via; Siemens
Medical Solutions, Malvern, PA).
For localizing insulinomas, SPECT/CT (4 and 72 hours post-
injection) and PET/CT readings were previously carried out in a
randomized, blinded manner by 3 board-certified nuclear medicine
physicians. All readers were unaware of the patient’s identity, other
imaging results, and the patient’s clinical history and assessed im-
ages independent from each other.
On visual analysis, abnormal uptake (focal or segmental) was
determined as positive for an insulinoma or nesidioblastosis when
the lesion exhibited a nonphysiological increased uptake that was
clearly visible and discernible from background activity. False read-
ing was defined as follows: (1) false-negative reading: insulinoma/
nesidioblastosis missed by readers and (2) false-positive reading
was defined as physiological uptake interpreted by readers as
insulinoma or nesidioblastosis.
Quantitative analysis was performed by a nonblinded nuclear
medicine physician:
For the calculation of insulinoma-to-background ratios,
duodenum-to-background ratios, and insulinoma-to-duodenum ratios,
spherical volumes of interest were placed over the regions of normal
pancreatic tissue (background), first and second parts of the duodenum
(pancreaticoduodenal uptake), and areas of focal or segmental in-
creased pancreatic uptake (insulinomas, nesidioblastosis) on PET/
CT and SPECT/CT scans.
The same nonblinded nuclear medicine physician assessed
scans and clinical information to determine the size and localization
of insulinomas, as well as the presence of nesidioblastosis.
RESULTS
Figure 1 illustrates the participant selection and outcome
flow figure, whereas the main results are summarized in Table 1.
The physiological 111In-exendin-4 and 68Ga-DOTA-exendin-4 dis-
tribution of a patient with a normal whole-body scintigraphy,
SPECT/CT, and PET/CT scan is shown in Figure 2. Independent
reading of GLP-1R scans revealed false-negative results in 7.1%
of PET/CT and 20.5% of SPECT/CT scans. There was no false-
positive reading. By further evaluation of false-negative reading
results, the following pitfalls could be identified: peripancreatic
uptake, small lesions, kidney overlap, and diffuse increased pan-
creatic uptake (Table 1).
Peripancreatic Uptake
Specific radiotracer accumulation in GLP-1R–positive
Brunner glands located in the proximal duodenum (pancreaticoduodenal
uptake) was the most common pitfall (100% incidence) and was
FIGURE 1. Participant selection and outcome flow figure. *The incidence of pitfalls is given as absolute number and percentage
in a per-patient analysis. †Based on the fact that all duodenal Brunner glands of the duodenum exhibit uptake in a variable
degree. §Reference standard was at least 2 repetitive MRI scans and follow-up of neuroglycopenic symptoms. ‡Reference
standard was surgery with histopathological/immunohistological evaluation.
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Total No. Readings† Type of False Reading
SPECT/CT:
False Readings/




Pancreaticoduodenal uptake 52/52† (100%) 1/156 (0.6%) FN 14/156 (9.0%) FN
Ectopic insulinoma 2/52 (4%) 0/156 (0%) None 4/156 (2.6%) FN
Small lesions (diameter <1 cm)
Small insulinomas‡ 11/52 (21%) 3/156 (1.9%) FN 8/156 (5.1%) FN
Kidney overlap
Insulinoma overlap with kidneys 3/52 (6%) 3/156 (1.9%) FN 7/156 (4.5%) FN
Diffuse increased pancreas uptake
Nesidioblastosis 1/52 (2%) 1/156 (0.6%) FN 3/156 (1.9%) FN
Total 52/52 (100%) 8/156 (5.1%) FN 32/156 (20.5%) FN
*The incidence of pitfalls is given as absolute number and percentage in a per-patient analysis. False reading results are given as number of false reading per total number of
readings (3 readers  52 patients = 156 readings) for PET/CT and SPECT/CT in the same patient cohort.
†Based on the fact that all duodenal Brunner glands of the duodenum exhibit uptake in a variable degree.
‡Small insulinomas(<1 cm) include multiple small insulinomas in 3 of 52 patients with MEN-1.
FN indicates false negative.
FIGURE 2. Normal scan (patient 11): full body scan acquired 72 hours after the injection of 111In-DOTA-exendin-4 shows the
physiological distribution with moderate uptake in the salivary glands, diffuse uptake in the pancreas, and renal radiotracer
excretion through the kidneys with subsequent accumulation in the bladder (A). Transaxial SPECT/CT acquired 72 hours after
the injection of 111In-DOTA-exendin-4 shows physiological, diffuse uptake in the pancreas (arrows) and renal radiotracer
accumulation (B). Maximum intensity projection image 2.5 hours after injection of 68Ga-DOTA-exendin-4 shows physiological
radiotracer distribution with moderate uptake in the salivary glands, discrete mediastinal blood pool activity, diffuse uptake in
the pancreas, and renal excretion through the kidneys with subsequent accumulation in the bladder (C). Representative
transaxial 68Ga-DOTA-exendin-4 PET/CT image shows the physiological moderate radiotracer uptake in the pancreas (arrows)
and renal accumulation (D).
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therefore almost always the reason for peripancreatic uptake of
radiolabeled exendin-4 (Fig. 3). Two ectopic insulinomas were
identified as the only exception (Fig. 4). Pancreaticoduodenal up-
take did mislead the readers in their interpretation especially in
111In-DOTA-exendin-4 SPECT/CT scans resulting in false-
negative reading results (falsely interpreted as physiological up-
take in Brunner glands instead of insulinomas): in 0.6% (1/156)
false-negative readings with PET/CT and 9.0% (14/156) false-
negative readings with SPECT/CT (Table 1). Because reading
was done by 3 nuclear medicine physicians, a total of 156 read-
ings were done (3 readers  52 patients = 156 readings).
PET/CT performed much better in this situation, correlating
with the quantitative analysis, which revealed a median insulinoma-
to-duodenum ratio of 2.95 for PET/CT and only 1.72 and 1.84 for
SPECT/CT at 4 and 72 hours (Table 2 and Fig. 3).
Table 2 shows the comparison of uptake ratios between
2.5 hours PET/CT, 4 hours SPECT/CT, and 72 hours SPECT/CT.
Small Lesions
Eleven patients had a small insulinoma (diameter <1 cm).
Three (1.9%) of 156 false-negative readings occurred in PET/CT
in comparison to SPECT/CT with 8 (5.1%) of 156 false-negative
readings (Table 1 and Fig. 4). Three of those 11 patients have genet-
ically proven MEN-1 (Fig. 5).
Kidney Overlap
Three insulinomas were located in the distal pancreatic tail,
close to the kidney. Three (1.9%) of 156 false-negative readings oc-
curred with PET/CT in comparison to SPECT/CTwith 7 (4.5%) of
156 false-negative readings (Fig. 6).
Diffuse Increased Pancreatic Uptake
One patient had a histopathologically proven nesidioblastosis.
Only 1 PET/CT reader (1/156 [0.6%]) read false-negative, whereas
FIGURE 3. Insulinoma and pancreaticoduodenal uptake (patient 2): transaxial SPECT/CT depicts a histopathologically proven
insulinoma in the pancreatic tail (arrow) with maximum count of 20.5 (A). Transaxial PET/CT shows a histopathologically
proven insulinoma in the pancreatic tail (arrow) with an SUVmax of 10.4 (B). Transaxial SPECT/CT of the same patient depicts a
physiological pancreaticoduodenal uptake (arrow) in Brunner glands with maximum count of 21.5 (C). Transaxial PET/CT
shows a physiological pancreaticoduodenal uptake (arrow) in Brunner glands with an SUVmax of 5.3 (D).
FIGURE 4. A small, ectopic insulinoma (patient 12): transaxial SPECT/CT acquired 72 hours after the injection of 111In-DOTA-
exendin-4 shows physiological renal tracer accumulation but no pathological uptake in the abdomen (A). Transaxial PET/CT
2.5 hours after injection of 68Ga-DOTA-exendin-4 of the same patient shows a clear focal uptake in the peripancreatic fat
consistent with an insulinoma (arrow) (B). Transaxial T2 weighted MRI shows a 5-mm measuring lesion (arrow) in the
peripancreatic fat in correlation with previously performed PET/CT (C).
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all SPECT/CT readers (3/156 [1.9%]) were not able to identify the
nesidioblastosis (Fig. 7).
DISCUSSION
The increasing availability of GLP-1R imaging with PET
tracers such as 68Ga-DOTA-exendin-4 and 68Ga-NODAGA-
exendin-4 or SPECT tracers such as 99mTc-HYNIC-exendin-4,
111In-DOTA-exendin-4, or 111In-DTPA-exendin-4 raises the need
for awareness of potential pitfalls in image interpretation.
In this post hoc analysis of our prospective study involving
52 patients, we were able to identify several potential pitfalls, which
can be classified into 2 major groups: scan with peripancreatic up-
take and scan with missing focal pancreas uptake.
Scan With Peripancreatic Uptake
Accumulation of GLP-1R–specific radiotracers in Brunner
glands is responsible for the physiological peripancreatic uptake.9
It is the most common pitfall as Brunner glands are always present
and accountable for the pancreaticoduodenal uptake, which can
cause confusion for the readers: Brunner glands versus insulinoma.
Brunner glands including Brunner glands hyperplasia have
been shown in ex vivo immunohistochemistry staining and autora-
diography to express GLP-1R in high density, making them relevant
targets for GLP-1R specific radiotracers.8,9 These glands are lo-
cated in the proximal duodenum and secrete a protective layer
against gastric acid and digestive enzymes.10 Christ et al11 first re-
ported in 2013 that Brunner glands may be an explanation for
false-positive results in GLP-1R SPECT/CT. False-positive results
due to pancreaticoduodenal uptake possibly lead to relevant clinical
consequences, as lesions located in the pancreatic head are mostly
resected through duodenopancreatectomy (Whipple surgery), in
case enucleation is not possible. Therefore, a high diagnostic confi-
dence in the evaluation of focal pancreaticoduodenal uptake is de-
sirable. In insulinomas located in the pancreatic head, GLP-1R
PET/CT encountered far fewer false readings in comparison to
SPECT/CT (0.6% vs 9.0% false readings, respectively). In all these
false readings, insulinomas located in the pancreatic head were
misinterpreted as unspecific Brunner glands uptake and were there-
fore missed (false-negative reading).
The lower rate of false readings in PET/CT can be explained
by the results of quantitative measures. Although insulinoma-to-
background ratio was higher than duodenum-to-background ratio
in both PET/CTand SPECT/CT, the difference in ratios was clearly
less pronounced in SPECT/CT, which had an influence in the read-
ing confidence in pancreaticoduodenal uptakes.
Consequently, if SPECT/CT is used in GLP-1R imaging,
morphological correlation, preferably with MRI,12 is mandatory
to reduce misinterpretation, especially if lesions are suspected in
the pancreatic head.
Ectopic insulinomas, although extremely rare,13 can be an-
other cause for peripancreatic uptake as they can occur anywhere
in the peripancreatic fat or in the duodenal wall14 (Fig. 4).
Scan With Missing Focal Pancreatic Uptake
Biochemical evidence for an insulinoma but absence of focal
radiotracer uptake in the pancreas might occur in the following sit-
uations: (1) insulinoma is not localized in the pancreas (ectopic
insulinoma); (2) insulinomas are too small to be detected with
PET/CT or SPECT/CT; (3) insulinomas overlap with kidneys; and
(4) EHH is caused by beta-cell hyperplasia (nesidioblastosis) and
not by an insulinoma.
(1) Ectopic insulinomas: Although extremely rare,13 ectopic
insulinomas can be the reason for missing focal uptake in the pan-
creas as they can occur anywhere in the peripancreatic fat or in the
duodenal wall.14 In our study, 2 patients with high suspicion
for an ectopic insulinoma were identified with 68Ga-DOTA-
exendin-4 PET/CT. One of those 2 patients received extensive
diagnostic workup since 2010, leading to a (blind) pancreatic
left resection, which did not reveal any suspicious lesion. Also,
GLP-1R SPECT/CT performed 2 years later did not reveal any
suspicious lesion. However, both 68Ga-DOTA-exendin-4 PET/
TABLE 2. Comparison of Uptake Ratios Between 2.5 Hours PET/CT, 4 Hours SPECT/CT, and 72 Hours SPECT/CT
Imaging Modality Insulinoma-to-Background Ratio Duodenum-to-Background Ratio Insulinoma-to-Duodenum Ratio
2.5 h PET/CT 3.45 (2.26–5.58) 1.17 (0.98–1.59) 2.95 (1.68–4.76)
4 h SPECT/CT 2.17 (1.62–3.95) 1.26 (0.78–2.51) 1.72 (1.01–2.58)
72 h SPECT/CT 2.19 (1.53–3.20) 1.19 (0.79–1.60) 1.84 (1.26–3.36)
Data are expressed in median (IQR).
FIGURE 5. Multiple insulinomas including 1 small insulinoma (patient 46): transaxial SPECT/CT of a patient with MEN-1 and
EHH acquired 72 hours after the injection of 111In-DOTA-exendin-4 depicts 2 lesions in the pancreas (small arrows) (A).
Histology revealed 2 insulinomas with a diameter of 17 and 11 mm. Transaxial PET/CT 2.5 hours after injection of 68Ga-DOTA-
exendin-4 of the same patient shows 1 additional lesion (large arrow) in the pancreatic tail consistent with an additional,
histopathologically proven insulinoma with a diameter of 6 mm (B).
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CTs performed in January 2014 and August 2016 showed an
intensive focal uptake in a small lesion in the peripancreatic fat
anterior to the pancreatic body compatible with an insulinoma.
The other patient was diagnosed with EHH in 2004, henceforth
received extensive diagnostic workup, including ASVS in 2009,
distal pancreatectomy in 2012, and repeat explorative laparotomy
in 2014. Glucagon-like peptide-1 receptor PET/CT in 2014 re-
vealed a clear focal uptake in the peripancreatic fat just below
the pancreatic head (Fig. 4). Unfortunately, both patients refused
additional surgery due to previous unsuccessful surgery. The
standard for comparison in both patients was 2 positive repetitive
MRI scans and continuation of neuroglycopenic symptoms. Ec-
topic insulinomas should be considered as a differential diagnosis
in patients with EEH and missing evidence of focal radiotracer
uptake in the pancreas. In such cases, the peripancreatic region
should be screened for areas of focal increased uptake, which is
a sign for the presence of an ectopic insulinoma.
(2) Small insulinomas: Despite not being a real pitfall, the most
common cause for missing 68Ga-exendin-4 or 111In-exendin-4
uptake in the pancreas is the small size of the insulinoma. Espe-
cially lesions with a diameter of less than 10 mm are a major
problem as they are often below the scanner sensitivity of GLP-
1R imaging. Eleven (21.2%) of 52 patients had an insulinoma
with a diameter of 10 mm or less; 1.9% false-negative readings
occurred with PET/CT in comparison to 5.1% false-negative
readings for SPECT/CT. The better performance of PET/CT is at-
tributed to the higher spatial resolution and sensitivity of PET/CT,
which is able to detect insulinomas up to a size of 4 mm.5 This is
also true in patients with MEN-1 who often have multiple small
insulinomas.5 In the case of negative GLP-1R scan and negative
morphological imaging, a repeat GLP-1R scan after 1 or 2 years
should be considered as possible lesion growth may increase the
probability that the occult tumor will be depicted.15
(3) Insulinoma overlap with kidneys: Localization of insulinomas
close to the kidney can be problematic, as the excretion of GLP-
1R specific radiotracers is mainly via the urinary tract.16 Espe-
cially lesions located close to the kidneys can be masked due to
the high renal uptake.17 The inherent high partial volume effect
is thus a known limitation and potential pitfall of GLP-1R imag-
ing. The aforementioned effect is less pronounced in PET/CT
than in SPECT/CT owing to the higher spatial resolution of
PET/CT,18 which reflects in the lower false-negative reading rate
of PET/CT (1.9%) in comparison to SPECT/CT (4.5%). Careful
inspection in the kidney contours can increase detectability of
insulinomas localized close to the kidney, as a characteristic bulge
within the contour might be identified (Fig. 6). In case of negative
GLP-1R imaging, correlation with MRI or CT is recommended
in order to identify a possible insulinoma close to the kidneys.
If such a correlation is not successful, and the patient has persis-
tent hypoglycemia, a considerable reduction in renal GLP-1R
tracer uptake can be accomplished through the prior infusion
of Gelofusion, a plasma expander known to induce low-
molecular-weight proteinuria.17,19,20 The off-label use of this
infusion may improve the detection of lesions close to the kid-
neys as previously published.17,21
In case of all noninvasive imaging and localization procedures
being negative, selective intra-ASVS should still be considered.
(4) Nesidioblastosis: Beta-cell hyperplasia (nesidioblastosis)
is a differential diagnosis of EHH.22,23 In this situation, the
clinical distinction to EHH caused by insulinomas is normally
FIGURE 6. Insulinoma overlap with kidneys (patient 6): 111In-DOTA-exendin-4 SPECT/CT showed radiotracer accumulation
only in the kidneys but no evidence of an insulinoma (A). 68Ga-DOTA-exendin-4 PET/CT of the same patient showed strong
focal uptake within the distal pancreatic tail (arrow) consistent with a histologically proven insulinoma (B).
FIGURE 7. Nesidioblastosis (patient 5): transaxial SPECT/CT acquired 72 hours after the injection of 111In-DOTA-exendin-4
shows no pathological radiotracer accumulation (A). Transaxial PET/CT of the same patient acquired 2.5 hours after injection
of 68Ga-DOTA-exendin-4 shows a pathological radiotracer uptake in the pancreatic tail consistent with a histopathologically
proven nesidioblastosis (B).
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not possible. In addition, morphological imaging using CT,
MRI, or endoscopic ultrasound is not helpful in the detection
of nesidioblastosis. Often only ASVS is helpful to identify/
localize focal nesidioblastosis, but comes along with the associated
risk of an invasive procedure. In a recent case report, we were able
to show that GLP-1R PET/CT may be able to localize focal or seg-
mental areas of nesidioblastosis.6 In this patient, GLP-1R PET/CT
indicated the area of diffuse uptake in the pancreatic tail. Based
on these findings, a left-sided pancreatectomy was performed,
and histology confirmed the presence of a nesidioblastosis. All
3 SPECT readers were false-negative in this patient. Therefore,
nesidioblastosis should always be considered as a differential diag-
nosis in patients with EHH andmissing evidence of focal radiotracer
uptake. In such a case, the pancreas should be screened for areas of
diffuse increased 68Ga-exendin-4 uptake, which may be an indica-
tion for the presence of beta-cell hyperplasia (nesidioblastosis).
This study has limitations. (1) Evaluation of pitfalls was per-
formed only with DOTA-exendin-4 tracers. Other clinically evaluated
exendin-4 derivatives, such as [Lys40(Ahx-HYNIC- 99mTc/EDDA)
NH2]-exendin-4,
24 68Ga-NODAGA-exendin-4,25 and 111In-DTPA-
exendin-4,1 as well as preclinically evaluated tracers,26 have not been
evaluated in this study. Pitfalls may vary in these derivatives. (2) Pa-
tients with signs of malignancy on conventional imaging were ex-
cluded in this study, although few case reports exist that showed
GLP-1R imaging is feasible and detects malignant insulinomas.3
As opposed to benign insulinomas, malignant insulinomas often
lack GLP-1 receptors and conversely frequently express the so-
matostatin receptor type 2.4
CONCLUSIONS
Peripancreatic uptake, small size of an insulinoma, insulinoma
overlap with kidneys, and the presence of nesidioblastosis are potential
pitfalls in GLP-1R imaging, which can lead to false reading results.
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